Testosterone therapy in men with classical versus functional hypogonadism: results from a controlled 9-years, real-world registry study.

The therapeutic outcomes of TTh across distinct hypogonadal populations demonstrate heterogeneous responses, significantly influenced by diagnostic categorization, age, and baseline risk factor profiles.